10.6084/m9.figshare.11665008.v1
Jiahang Mo
Jiahang
Mo
Xiao Hu
Xiao
Hu
Lihu Gu
Lihu
Gu
Bangsheng Chen
Bangsheng
Chen
Parikshit Khadaroo
Parikshit
Khadaroo
Zefeng Shen
Zefeng
Shen
Lei Dong
Lei
Dong
Yuqi Lv
Yuqi
Lv
Marylin Chitumba
Marylin
Chitumba
Jiequan Liu
Jiequan
Liu
MOESM3 of Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Springer Nature
2020
Smoking
Immunotherapy
Immune checkpoint inhibitors
Anti-PD-1/PD-L1
Meta-analysis
2020-01-21 05:11:50
Figure
https://springernature.figshare.com/articles/figure/MOESM3_of_Smokers_or_non-smokers_who_benefits_more_from_immune_checkpoint_inhibitors_in_treatment_of_malignancies_An_up-to-date_meta-analysis/11665008
Additional file 3: Figure S3. Forest plot of the long-term prognostic outcomes of anti-PD-1/PD-L1 monotherapy in NSCLC (Non-smoker vs. Smoker), PNon-smoker=0.921, PSmoker<0.001.